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Abstract
In this randomized clinical trial, the clinical and mycological efﬁcacy of Photodynamic Therapy (PDT) was compared with that of topical
antifungal therapy for the treatment of denture stomatitis (DS) and the prevalence of Candida species was identiﬁed. Patients were ran-
domly assigned to one of two groups (n = 20 each); in the nystatin (NYT) group patients received topical treatment with nystatin
(100 000 IU) four times daily for 15 days and in the PDT group the denture and palate of patients were sprayed with 500 mg/L of
Photogem, and after 30 min of incubation, were illuminated by light emitting-diode light at 455 nm (37.5 and 122 J/cm2, respectively)
three times a week for 15 days. Mycological cultures taken from dentures and palates and standard photographs of the palates were
taken at baseline (day 0), at the end of the treatment (day 15) and at the follow-up time intervals (days 30, 60 and 90). Colonies were
quantiﬁed (CFU/mL) and identiﬁed by biochemical tests. Data were analysed by Fisher’s exact test, analysis of variance and Tukey tests
and j test (a = 0.05). Both treatments signiﬁcantly reduced the CFU/mL at the end of the treatments and on day 30 of the follow-up
period (p <0.05). The NYT and PDT groups showed clinical success rates of 53% and 45%, respectively. Candida albicans was the most
prevalent species identiﬁed. PDT was as effective as topical nystatin in the treatment of DS.
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Abstract
The study aimed to identify targets for quality improvement in antifungal use in European hospitals and determine the variability of such
prescribing. Hospitals that participated in the European Surveillance of Antimicrobial Consumption Point Prevalence Surveys (ESAC-
PPS) were included. The WHO Anatomical Therapeutic Chemical (ATC) classiﬁcation for ‘antimycotics for systemic use’ (J02) 2009 ver-
sion was used. Demographic data and information about indications and diagnoses were collected in 2008 and 2009. From 99 053
patients, 29 324 (29.6%) received antimicrobials. Antifungals represented 1529 of 40 878 (3.7%) antimicrobials. Antifungals were mainly
(54.2%) administered orally. Hospital-acquired infections represented 44.5% of indications for antifungals followed by medical prophy-
laxis at 31.2%. The site of infection was not deﬁned in 36.0% of cases but the most commonly targeted sites were respiratory (19.2%)
and gastrointestinal (18.8%). The most used antifungal was ﬂuconazole (60.5%) followed by caspofungin (10.5%). Antifungal–antibacterial
combinations were frequently used (77.5%). The predominance of ﬂuconazole use in participating hospitals could result in an increase in
prevalence of inherently resistant fungi, increasing the need for newer antifungals. Although acknowledging that antifungal prophylaxis in
the immunocompromised host needs further exploration, repetitive surveys using ESAC-PPS methodology may help to monitor the
effects of interventions set to regulate antifungal use.
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